NASDAQ: LUCYInnovative Eyewear Inc Stock
$0.80-0.06 (-6.98%)
Updated Jun 18, 2026
LUCY Price
$0.80
Fair Value Price
N/A
Market Cap
$5.12M
52 Week Low
$0.80
52 Week High
$2.90
P/E
-0.47x
P/B
0.61x
P/S
2.28x
PEG
N/A
Dividend Yield
N/A
Revenue
$2.98M
Earnings
-$8.12M
Gross Margin
17.5%
Operating Margin
-272.48%
Profit Margin
-272.5%
Debt to Equity
0.13
Operating Cash Flow
-$7M
Beta
1.06
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
LUCY Overview
Innovative Eyewear, Inc. specializes in the design and commercialization of intelligent eyewear, encompassing both eyeglasses and sunglasses. Central to its product line is Lucyd Lyte, a pair of smart glasses empowering users to engage with audio content, manage phone conversations, and activate smartphone functions hands-free through voice commands. Additionally, the company provides Vyrb, a social media application facilitating the vocal exchange of posts directly through Lucyd Lyte smart glasses. Its offerings reach consumers via diverse e-commerce platforms and traditional retail outlets. Established in 2019 and headquartered in North Miami, Florida, Innovative Eyewear, Inc. operates as a subsidiary of Lucyd Ltd., reflecting its close collaboration with the latter.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine LUCY's potential to beat the market
- LUCY doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical
Industry Rating
A
LUCY
RankedUnranked of 42
RankedUnranked of 42
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.42 | A | |
| $22.02 | B | |
| $14.87 | B |
Be the first to know about important LUCY news, forecast changes, insider trades & much more!
LUCY News
Overview
Due Diligence Score
–
Industry Average (30)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how LUCY scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LUCY is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
LUCY is good value based on its book value relative to its share price (0.61x), compared to the US Medical Instruments & Supplies industry average (3.15x)
P/B vs Industry Valuation
LUCY is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more LUCY due diligence checks available for Premium users.
Valuation
LUCY price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.47x
Industry
42.33x
Market
9.47x
LUCY price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.61x
Industry
3.15x
LUCY is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
LUCY's financial health
Profit margin
Revenue
$773.6k
Net Income
-$2.3M
Profit Margin
-298.5%
LUCY's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
LUCY's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$9.5M
Liabilities
$1.1M
Debt to equity
0.13
LUCY's short-term assets ($8.75M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LUCY's short-term assets ($8.75M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LUCY's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.5M
Investing
-$1.0M
Financing
$1.4M
LUCY's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
LUCY vs Medical Stocks
Innovative Eyewear Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.